WorldOne snaps up Sermo

Share this article:
Sermo now counts Pfizer among its clients
Sermo now counts Pfizer among its clients
WorldOne has acquired Sermo, adding the physician social network's 130,000-strong physician community to its own global network of 1.7 million healthcare professionals.

Terms of the deal were not disclosed. WorldOne, a New York-based healthcare data firm, boasts that its panel offering draws from more than a million verified physicians across 80 countries. The firm merged its US health marketing research panel with that of Physicians Interactive as part of a strategic alliance back in January, giving it a panel of 300,000 AMA-verified doctors, nurses and allied health professionals. The addition of Sermo, said the firm, will boost reach, client list match rates and research opportunities.

“Sermo fits in perfectly with our strategy to extend our digital footprint across healthcare market research and enhance our growing portfolio of innovative engagement solutions,” said WorldOne CEO Peter Kirk in a statement. “Sermo has proven that sustaining an active, engaged community can result in higher interest in and response to market research as well as new promotional opportunities. Combining Sermo's technology and social media expertise with WorldOne's global scale enables us to rapidly accelerate our growth while offering the most enriching, collaborative online environment for physicians anywhere in the world.”

Cambridge, MA-based Sermo launched six years ago and has since assembled a substantial US physician community and inked deals with a few big drug companies, but the company has struggled to shift out of startup mode and realize a profit, and that's allowed would-be competitors like Doximity room to grow. The company's founder, Dr. Daniel Palestrant, MD, left along with the site's chief medical officer in November. In May, Sermo named former Revolution Health president Tim Davenport CEO.

A Sermo spokesperson said “key members of executive management involved in the day-to-day operations of the Sermo community are joining WorldOne.” Davenport will stay on for a time to work on the transition, said the firm.

“As Sermo grew the most vibrant online physician community in the US and, more recently, provided clients more robust research and promotion opportunities, clients asked for global reach and more key specialists,” said Davenport in a statement. “WorldOne adds both of these overnight, while Sermo greatly augments WorldOne's online and interactive business.”
Share this article:
You must be a registered member of MMM to post a comment.

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...